Keri Toner, MD
Washington, District of Columbia 20010
National Provider ID: 1417392036
Keri Toner is a member of the Leukemia and Lymphoma Program, Division of Blood and Marrow Transplant and CAR-T program. Her research interests include immunotherapy for high-risk hematologic malignancies.
Oncologists receive Hyundai Hope on Wheels grants
T-cell therapy alone or combined with nivolumab is safe and persistent in attacking Hodgkin’s lymphoma cells
T cell therapy alone or combined with cancer drug nivolumab is safe and persistent in attacking Hodgkin's lymphoma cells